Frequency of GAA- FGF14 Ataxia in a Large Cohort of Brazilian Patients With Unsolved Adult-Onset Cerebellar Ataxia
- PMID: 37646005
- PMCID: PMC10461713
- DOI: 10.1212/NXG.0000000000200094
Frequency of GAA- FGF14 Ataxia in a Large Cohort of Brazilian Patients With Unsolved Adult-Onset Cerebellar Ataxia
Abstract
Objectives: Intronic FGF14 GAA repeat expansions have recently been found to be a common cause of hereditary ataxia (GAA-FGF14 ataxia; SCA27B). The global epidemiology and regional prevalence of this newly reported disorder remain to be established. In this study, we investigated the frequency of GAA-FGF14 ataxia in a large cohort of Brazilian patients with unsolved adult-onset ataxia.
Methods: We recruited 93 index patients with genetically unsolved adult-onset ataxia despite extensive genetic investigation and genotyped the FGF14 repeat locus. Patients were recruited across 4 different regions of Brazil.
Results: Of the 93 index patients, 8 (9%) carried an FGF14 (GAA)≥250 expansion. The expansion was also identified in 1 affected relative. Seven patients were of European descent, 1 was of African descent, and 1was of admixed American ancestry. One patient carrying a (GAA)376 expansion developed ataxia at age 28 years, confirming that GAA-FGF14 ataxia can occur before the age of 30 years. One patient displayed episodic symptoms, while none had downbeat nystagmus. Cerebellar atrophy was observed on brain MRI in 7 of 8 patients (87%).
Discussion: Our results suggest that GAA-FGF14 ataxia is a common cause of adult-onset ataxia in the Brazilian population, although larger studies are needed to fully define its epidemiology.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Conflict of interest statement
L.E. Novis, R.S. Frezatti, D. Pellerin., P.J. Tomaselli, S. Alavi, M.V. Della Coleta, M. Spitz, M.-J. Dicaire, P. Iruzubieta, J.L. Pedroso, O. Barsottini, A. Cortese, and M.C. Danzi report no disclosures. M.C. França Jr took part as a PI in a clinical trial for Friedreich ataxia, sponsored by PTC, and received research funding from Friedreich ataxia research alliance. None of these related to the current study. B. Brais reports no disclosures. S. Zuchner is a consultant on drug targets for Aeglea BioTherapeutics and consultant on clinical trial design for Applied Therapeutics, all of them unrelated to the work in the present manuscript. H. Houlden, S. Raskin, W. Marques, and H.A. Teive report no disclosures. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.
Figures

References
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous